Drug Trial Radar · NCT07229716
Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Apr 4, 2026
Primary completion
Jun 18, 2026
Study completion Jun 18, 2026
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.
Conditions
- Pulmonary Fibrosis
Interventions
HRS-9813 CapsuleDrug
HRS-9813 capsule, specified dose on specified days.
Nintedanib Soft CapsulesDrug
Nintedanib soft capsules, specified dose on specified days.
Pirfenidone TabletsDrug
Pirfenidone tablets, specified dose on specified days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The maximum plasma concentration (Cmax)Time frame: From Day 1 to Day 24.
- Area under the concentration curve from time 0 to extrapolated infinite time (AUC0-inf)Time frame: From Day 1 to Day 24.
- Area under the concentration curve from time 0 to time of last quantifiable concentration (AUC0-tau)Time frame: From Day 1 to Day 24.
- Area under the concentration curve from time 0 to time t (AUC0-t)Time frame: From Day 1 to Day 24.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tangdu Hospital, Fourth Military Medical University
Xi’an, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.